Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling
| Autor: | Jing Liu, Jian Wang, Wenjian Hu, Zhong Lunkun |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine medicine.medical_treatment Cetuximab Mice Nude Antineoplastic Agents Apoptosis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Cyclin D1 In vivo Cell Line Tumor Antineoplastic Combined Chemotherapy Protocols Animals Humans Medicine Epidermal growth factor receptor Apigenin Phosphorylation Cell Proliferation Pharmacology Chemotherapy Nasopharyngeal Carcinoma biology business.industry Carcinoma Cell Cycle Nasopharyngeal Neoplasms General Medicine medicine.disease ErbB Receptors Radiation therapy 030104 developmental biology chemistry Nasopharyngeal carcinoma 030220 oncology & carcinogenesis Cancer research biology.protein business Signal Transduction medicine.drug |
| Zdroj: | Biomedicine & Pharmacotherapy. 102:681-688 |
| ISSN: | 0753-3322 |
| DOI: | 10.1016/j.biopha.2018.03.111 |
| Popis: | Nasopharyngeal carcinoma (NPC) is a type of head and neck cancers with poor prognosis. Despite that platinum-based chemotherapy concurrent with radiotherapy have made great achievements for the treatment of NPC, the therapeutic reaction and toxicity varies dramatically among individuals. Apigenin (API), a naturally occurring plant flavone, is considered to have anti-cancer effect. Cetuximab (CET), a well known epidermal growth factor receptor (EGFR) inhibitor, is widely used in various cancers, especially head and neck cancers. The aim of our study was to measure the combination of API and CET for the treatment of NPC in vitro and in vivo. Results demonstrated that combining API and CET could better suppress the viability of the human nasopharyngeal carcinoma cell lines (HONE1 and CNE2) and inhibit the growth of NPC than API or CET used alone. Besides, the combination of API with CET produced greater pro-apoptosis effect. Moreover, the increased G2/M phase arrest caused by CET could be remarkably enhanced by adding API in HONE1 and CNE2 cells. Although, both API and CET could decrease the expressions of p-EGFR, p-Akt, p-STAT3 and Cyclin D1. Combining them produced greater inhibition effect. These results suggested that the combination of API and CET may be a promising therapeutic approach for the treatment of NPC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect